Investigational drug · Phase 3
HSK21542
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Postoperative Pain Management.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
21
Any phase or sponsor naming "HSK21542"
First trial start
2024
Sep 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HSK21542", any sponsor or status.
Conditions studied
As listed on its trial records.
- Postoperative Pain Management
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "HSK21542" as an intervention, largest first.
- A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients with Chronic Kidney Disease-Associated PruritusPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT05135390 · 545 participants · Start Jun 17, 2022 · Primary completion Jul 27, 2023
Drug: HSK21542; Placebo · For: Pruritus; Hemodialysis Patients with Moderate-to-Severe Pruritus
Sites: Nanjing, China; Hangzhou, China
- A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic SurgeryPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07186426 · 405 participants · Start Aug 5, 2025 · Primary completion Feb 24, 2026
Drug: HSK21542; Placebo and 1 more · For: Postoperative Pain Management
Sites: Beijing, China; Changsha, China
- A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain TreatmentPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT05390905 · 387 participants · Start Jun 8, 2022 · Primary completion Dec 16, 2022
Drug: HSK21542 Injection; Tramadol hydrochloride and 1 more · For: Postoperative Analgesia
Sites: Wuhan, China
- A Clinical Study to Evaluate Efficacy and Safety of HSK21542 for Postoperative Analgesia of Subjects Undergoing Elective Laparoscopic Surgery Under General AnesthesiaPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT04738357 · 276 participants · Start Mar 24, 2021 · Primary completion Jul 30, 2021
Drug: HSK21542; Placebo · For: Postoperative Analgesia
Sites: Hangzhou, China
- A Study of HSK21542 in a Peritoneal Dialysis Pruritus Population.Pivotal-lookingStatus unknown
Xizang Haisco Pharmaceutical Co., LtdIndustry
NCT06290375 · 250 participants (planned) · Start Mar 8, 2024 · Primary completion Mar 8, 2024
Drug: HSK21542 tablet; Placebo · For: Pruritus
- A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in PONVPivotal-lookingCompleted
Sichuan Provincial People's HospitalAcademic, hospital or other
NCT06170476 · 200 participants · Start Nov 10, 2023 · Primary completion Feb 28, 2024
Drug: HSK21542-60μg; HSK21542-120μg and 2 more · For: Postoperative Nausea and Vomiting
Sites: Sichuan, China
- An Economic Study of HSK21542 Injection for Prevention of Postoperative Nausea and VomitingPivotal-lookingStatus unknown
Mengchang YangAcademic, hospital or other
NCT06359535 · 200 participants (planned) · Start Feb 23, 2024 · Primary completion Nov 6, 2024
Drug: HSK21542; Placebo · For: Nausea and Vomiting, Postoperative
Sites: Chengdu, China
- A Study Evaluating the Efficacy and Safety of HSK21542 Injection for Analgesia in Subjects Undergoing ColonoscopyPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT04470128 · 180 participants · Start Aug 19, 2020 · Primary completion Dec 28, 2020
Drug: Stage I: HSK21542 0.5 μg/kg; Stage I: HSK21542 1 μg/kg and 4 more · For: Analgesia
Sites: Chengdu, China
- Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and VomitingPivotal-lookingStatus unknown
First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06593782 · 180 participants (planned) · Start Sep 16, 2024 · Primary completion Jun 11, 2025
Drug: HSK21542; HSK21542 and 1 more · For: Nausea and Vomiting, Chemotherapy-Induced
- Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During ERCPPivotal-lookingRecruiting
The First Affiliated Hospital of Xinxiang Medical CollegeAcademic, hospital or other
NCT07376577 · 180 participants (planned) · Start Jan 1, 2026 · Primary completion Mar 2028
Drug: Sufentanil; Anricofen and 1 more · For: Anesthesia; Endoscopic Retrograde Cholangiopancreatography (ERCP)
Sites: Xinxiang, China
Newest research
PubMed records naming it or its code names, newest first.
- HSK21542 for Postoperative Analgesia in Gynecological Surgery: A Pooled Post-Hoc Analysis of Two Phase III Randomized Controlled Trials.
Yu S, Zou L, Dong S, et al. · Anesth Analg 2026
- Quantification of HSK21542 in rat plasma and tissues by LC-MS/MS: an application to pharmacokinetics and tissue distribution study.
Fang J, Wang Z, Cao K, et al. · Bioanalysis 2026
- Efficacy and Safety of Anrikefon (HSK21542) for Postoperative Pain. A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Azam MT, Shahid ZUA, Khan MA, et al. · J Pain Palliat Care Pharmacother 2026
- Commentary: Efficacy and safety of HSK21542 for pruritus management in hemodialysis patients: a multicenter, randomized, double-blind, placebo-controlled trial.
Fishbane S · Front Pharmacol 2025
- Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.
Liu BC, Li ZL, Zhang P, et al. · BMJ 2025
- Efficacy and safety of peripherally-restricted κ-opioid receptor agonist-HSK21542 for postoperative analgesia in patients undergoing laparoscopic abdominal surgery: a randomized, placebo-controlled phase 2 trial.
Zhong Y, Wang H, Yan M, et al. · Front Med (Lausanne) 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.